[1]Maria J,Miguel A,Kamel B.Importance of single or blended polymertypes for controlled in vitro release and plasma levels of a somatostatinanalogue entrapped in PLGA/PLA microspheres[J].J controlled Re-lease,2004,96(2):437-448.
[2]Gopferich A,Ploymer degradation and erosion:mechanism and appli-cations[J].Eur J Pharm Biopharm,1996,42(1):1-11.
[3]Gopferich A,Polymer bulk erosion[J].Macromolecules,30(12):2598-2604.
[4]Husmann M,Schenderlein S.Polymer erosion in PLGA microparticlesproduced by phase separation method[J].Int J Pharmaceutics,2002,242(6):227-280.
[5]Harish B,Kevin B,Patrick P.Polymer and microsphere blending toalter the release of a peptide from PLGA microspheres[J].Eur JPharm Biopharm,2000,50(6):251-262.
[6]Richard A,Sarala P,Raisa M.Effect of defferent ratios of high andlow molecular weight PLGA blend on the characteristics of pentami-dine microspheres[J].Int J Pharmaceutics,2004,270(40):277-280.
[7]Delphine M,Francois B,Fabien M.PLGA-PEG microspheres ofteverelix:influence of polymer type on microsphere characteristics andon teverelix in vitro release[J].Int J Pharmaceutics,2003,261(2):69-80.
[8]Hongkee S.Ethyl formate-alternative dispersed solvent useful inpreparing PLGA microspheres[J].Int J Pharm,2000,195(1):103-113.
[9]Hongkee S.Microencapsulation techniques using ethyl acetate as a dis-persed solvent effects of its extraction rate on the characteristics of PL-GA microspheres[J].J controlled Release,1997,47(2):233-245.
[10]Mesens,Jean,Louis,et al.Rate controlled transdermal administrationof risperidone[P].WO9631201,1996-10-10.
[11]Rickey,Ramstack,Lewis,et al.Microparticles[P].WO9741837,1997-11-13.
[12]Edith J,Nancy S,Jan Z.Preparation and characterization of PLGA mi-crospheres containing DFO[J].Int J Pharmaceutics,1997,153(6):235-245.
[13]Takahiro M,Yumi S,Yuji H.Protein encapsulation into biodegradableby a novel S/O/W emulsion method using PLGA as a protein mi-cronization adjuvant[J].J Controlled Release,2000,69(5):435-442.
[14]Carrascosa C,Torres C.Microspheres containing insulin-like growthfator I for treatment of chronic neurodegeneration[J].Biomaterials,2004,25(8):707-714.
[15]Donnell PB,Ginity JW.Influence of processing on the stability and re-lease properties of biodegradable microspheres containing thioridazinehydrochloride[J].Euro J Pharm Biopharm,1998,45(1):83-90.
[16]Cory B,Kyekyoon K,Daniel W.Fabrication of PLG microspheres withprecisely controlled and monodisperse size distributions[J].J Con-trolled Release,2001,73(1):59-74.
[17]Kimiko M,Takehisa N,Mitsuhiko S.Efficient intracellular delivery ofrifampicin to alveolar macrophages using rifampicin-loaded PLGAmicrospheres:effects of molecular weight and composition of PLGA onrelease of rifampicin[J].Collo Surf,2004,36(1):35-42.
[18]Fuminori I,Kimiko M.Preparation and properities of monodispersedrifampicin-loaded PLGA microsphere[J].Collo Surf,2004,39(1):17-21.
[19]Shinji S,Mitsutoshi N,Minoru S.Preparation of monodispersed poly-meric microsperes over 50μm employing microchannel emulsification[J].Ind Eng Chem Res,2002,41:4043-4047.
[20]Delia B,Nathan S,Debra W.Uniform paclitaxel-loaded biodegrad-able microspheres manufactured by Ink-Jet technology[C].the Win-ter Symposium and 11th International Symosium on Recent Advancesin Drug Delivery System,Salt-lake City,UT,2003.
[21]Ywujang F,Shinshing S,Fuhu S.Development of biodegradable PLGAmicrospheres for the controlled release of 5-FU by the spray dryingmethod[J].Colloids Surfaces,2002,6:269-279.
[22]Fang-jing W,Chihwa W.Sustained release of etanidazole from spraydried microspheres prepared by non-halogenated solvents[J].J Con-trolled Release,2002,81(4):263-280.
[23]Maryellen S,David E,Paula W.Effect of protein molecular weight onrelease from micron-sized PLGA microspheres[J].J Controlled Re-lease,2001,76(6):297-311.
[24]Fwulong M,Shinshing S,Yimei L.Chintin/PLGA blend microspheresas a biodegradable drug delivery system:a new delivery system forprotein[J].Biomaterials,2003,(11):5023-5036.
[25]陆丽芳,潘俊,陆伟跃.多肽几蛋白质类药物微球的研究进展[J].中国医药工业杂志,2004,35(2):113-116.
[26]Teng H,Jianjun W,Chihwa W.Double-wall microspheres for thesustained release of a highly water soluble drug:characterization irra-diation study[J].J Controlled Release,2002,83(7):437-452.
[27]Meng S,Yiyan Y,Chengshu C.Double walled POE/PLGA micro-spheres:encapsulation of water soluble and water insoluble proteinsand their release properties[J].J Controlled Release,2003,89(3):167-177.
[28]Sishen F,Gang R,Qiu-tian L.Fabrication and characterizations of anovel drug delivery device liposomes-in-microsphere(LIM)[J].Biomaterials,2004,25(15):5181-5189.
[29]Giuseppe T,Angela L,Giancarlo B.Encapsulation and release of thehypnotic agent zolpidem from biodegradable polymer microparticlescontaining hydroxypropyl-β-cyclodextrin[J].Int J Pharmaceutics,2003,268(1):47-57.
[30]Fabiana Q,Giuseppe D,Elena G.Feeding liquid,non-ionic surfac-tant and syslodextrin affect the propertees of insulin-loaded PLGAmicrospheres prepared by spray-drying[J].J Controlled Release,2003,86(3):267-278.
[31]Juan W,Barbara M,Steven P.Characterization of the initial burst re-lease of a model peptide from PLGA microspheres[J].J ControlledRelease,2002,82(3):289-307.
[32]Rajeev A,Christopher T,Aruna M.Controlled release of drugs frominjectable in situ formed biodegradable PLGA microspheres:effect ofvarious formulation variables[J].Eur J Pharm Biopharm,2000,50(4):257-262.
[33]Matthew J,Jagdish S.Effect of tricaprin on the physical characteristicsand in vitro release of etoposide from PLGA microspheres[J].Bioma-terials,2002,23(16):3465-3471.
[34]Jong E,Yoon S,Keum H.Conjugation of drug to PLGA for controlledrelease from biodegradable microspheres[J].J Controlled Release,1999,57(6):269-280.
[35]Anshul G,Kadriye C.Formulation and characterization of paclitaxel,5-Fu and paclitaxel+5-FU microspheres[J].Int J Pharmaceutics,2004,276(1):93-106.
